Goldman Sachs' latest report on China's biotechnology sector highlights Everest Medicines (1952.HK) as a company on track to achieve EBITDA break-even by the end of 2025. This outlook is driven by the accelerated commercialization of Nefecon(R), which was recently included in China's National Reimbursement Drug List (NRDL).
More info..

Everest Medicines (HKEX 1952.HK, Everest , or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that with the official implementation of the latest update of the National Reimbursement Drug List ('NRDL') on January 1, 2025, NEFECON will apply the NRDL pricing, which will benefit more IgA nephropathy (IgAN) patients.
More info..

Everest Medicines (HKEX 1952.HK, 'Everest', or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription for VELSIPITY(R) has been written at Foshan Fosun Chancheng Hospital in Guangdong, under the "Hong Kong and Macau Medicine and Equipment Connect" policy, which marks the official beginning of this new therapy benefiting patients in mainland China.
More info..

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the National Medical Products Administration (NMPA) of China has officially accepted the New Drug Application (NDA) for VELSIPITY (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC). VELSIPITY is an effective and convenient, once-daily, oral treatment for patients with moderately to severely active UC.
More info..

Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription of VELSIPITY(R) (etrasimod) has been issued on December 11th at Kiang Wu Hospital in Macau.
More info..

As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical company in the Asia-Pacific region, driven by robust R&D capabilities and exceptional commercialization expertise.
More info..

Everest Medicines (HKEX 1952.HK,"Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced positive results in the ongoing Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor.
More info..

Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everests New Drug Application (NDA) for VELSIPITY (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis.
More info..

On November 28, the National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security announced the 'National Reimbursement Drug List (2024)' (NRDL), which will officially take effect on January 1, 2025. NEFECON(R), the first etiological treatment for IgA nephropathy developed by Everest Medicines, was successfully included in the NRDL.
More info..

Today, Everest Medicines announced that NEFECON(R) has received full approval from the Ministry of Food and Drug Safety (MFDS) in South Korea, indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion =1.0 g/day (or urine protein-to-creatinine ratio =0.8 g/g). This approval further expands NEFECON(R)'s footprint in Asia and provides Asian patients with a groundbreaking etiological treatment option for IgAN.
More info..

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that, through the "Hong Kong and Macau Medicine and Equipment Connect" policy, VELSIPITY(R) has officially been approved for patients with moderately to severely active ulcerative colitis (UC) by the Guangdong Provincial Medical Products Administration and can first be used in the Foshan Fosun Chancheng Hospital and the First Affiliated Hospital of Sun Yat-sen University, two of the medical institutions designated by the "Hong Kong and Macau Medicine and Equipment Connect" policy in the Greater Bay Area.
More info..

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the "Kidney 360" magazine has published the complete two-year subpopulation data from Chinese patients in the Phase 3 NefIgArd clinical trial of NEFECON under the title "Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China: 2-Year NefIgArd Trial Results".
More info..

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Administration (TFDA) has approved NEFECON indicated "to reduce the loss of kidney function in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression1". There are no restrictions on initial proteinuria levels in the approved indication.
More info..

Everest Medicines (1952.HK) closed today with a 20.46% increase, hitting a high of HKD 28.6. The company's stock price has been steadily rising since the release of its interim results, with today's trading volume reaching HKD 291 million. Market updates show that BOCOM International released a report assigning an 'outperform' rating to the Chinese pharmaceutical sector, with Everest Medicines being one of the key recommended stocks.
More info..

Recently, Everest Medicines has announced another positive development. The company's lead product, NEFECON, as the only in-disease IgA nephropathy (IgAN) treatment, has been included in the "KDIGO 2024 Clinical Practice Guideline for the Management Of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)" (hereinafter referred to as the "New Guidelines (Draft)"), recommending treatment with a 9-month course of NEFECON for patients who are at risk of progressive kidney function loss with IgAN (2B).
More info..

Everest Medicines (HKEX 1952.HK, 'Everest', or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the launch of an Investigator-Initiated Clinical Trial (IIT) for a personalized mRNA cancer vaccine, EVM16, under the study EVM16CX01, at the Peking University Cancer Hospital and Fudan University's Cancer Hospital.
More info..